![Tony Kennedy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tony Kennedy
Chief Tech/Sci/R&D Officer at F2G Ltd.
Network origin in Tony Kennedy first degree
Entity | Entity type | Industry | |
---|---|---|---|
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Trigen Holdings AG
![]() Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany.
11
| Extinct | Miscellaneous Commercial Services | 11 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Tony Kennedy via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer Sales & Marketing | |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree | |
Novo Nordisk Ltd.
![]() Novo Nordisk Ltd. Medical/Nursing ServicesHealth Services Novo Nordisk Ltd. engages in the sale and marketing of pharmaceutical products for the treatment of chronic conditions in the United Kingdom. It offers medicines for the treatment of diabetes, and hemophilia and bleeding disorders, as well as for growth hormone therapy and hormone replacement therapy. The company is headquartered in Crawley, the United Kingdom. | Medical/Nursing Services | Director/Board Member Chairman | |
University of Uppsala | College/University | Undergraduate Degree Doctorate Degree | |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Director/Board Member Chairman | |
SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Sales & Marketing | |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor | |
BIO-WORKS TECHNOLOGIES AB | Biotechnology | Chairman Chairman | |
F2g Inc. | Director/Board Member President | ||
Gyros AB
![]() Gyros AB Medical SpecialtiesHealth Technology Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree Director/Board Member | |
Advent Venture Partners LLP
![]() Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Consultant / Advisor | |
New York Philharmonic
![]() New York Philharmonic Movies/EntertainmentConsumer Services New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY. | Movies/Entertainment | Director/Board Member | |
University of Geneva | College/University | Doctorate Degree | |
Sensimed SA
![]() Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Chairman | |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Chairman | |
Zentralinstitut für Seelische Gesundheit | Director/Board Member | ||
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Chief Tech/Sci/R&D Officer | |
BASF Pharma Ltd.
![]() BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Pharmaceuticals: Major | Founder | |
Bazando SAS
![]() Bazando SAS Information Technology ServicesTechnology Services Bazando SAS operates as a platform for online shopping. It allows users to browse through outsourced and crowd sourced brands and offers products at discounted prices. The firm's products include clothing, shoes, and accessories for women, men, and children. It also sells miscellaneous items for the home, such as pillows, chairs, decorations, and gadgets. The company was founded by Olivier Cotinat, Nicolas Baudran, and Jerome Pellegrin in 2007 and is headquartered in Colombelles, France. | Information Technology Services | Director/Board Member | |
Industrie Saleri Italo SpA
![]() Industrie Saleri Italo SpA Auto Parts: OEMProducer Manufacturing Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy. | Auto Parts: OEM | Director/Board Member | |
Stramongate SA | Investment Trusts/Mutual Funds | Chairman | |
HANSA INVESTMENT COMPANY LIMITED | Investment Managers | Director/Board Member | |
AQUAFIL S.P.A. | Textiles | Director/Board Member | |
BANCA INTERMOBILIARE DI INVESTIMENTI E GESTIONI S.P.A. | Investment Managers | Director/Board Member | |
INDUSTRIE DE NORA S.P.A. | Chemicals: Specialty | Director/Board Member | |
Fondazione Bruno Kessler | Investment Trusts/Mutual Funds | Director/Board Member | |
EVOLVA HOLDING SA | Food: Specialty/Candy | Chairman | |
THE EUROPEAN SMALLER COMPANIES TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member | |
Merifin Europe SA
![]() Merifin Europe SA Investment ManagersFinance Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes. | Investment Managers | Chief Investment Officer | |
The University of Manchester | College/University | Doctorate Degree | |
NBE-Therapeutics AG
![]() NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Chairman | |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member | |
ImevaX GmbH
![]() ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member | |
SUPERSONIC IMAGINE | Medical Specialties | Director/Board Member | |
A3P Biomedical AB
![]() A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Medical/Nursing Services | Chairman | |
Premalux AB | Director/Board Member | ||
Ac Intressenter AB | Chairman | ||
Sls Ventures AB | Director/Board Member | ||
3i Nordic Plc
![]() 3i Nordic Plc Investment ManagersFinance 3i Nordic Plc (3i Nordic) is the Swedish venture capital subsidiary of 3i Group Plc (LSE: III) in Great Britain. Formerly known as Atle AB, founded in 1993, the firm was acquired by 3i in 2001 and renamed 3i Nordic. Located in Stockholm, 3i Nordic utilizes specialized 3i Group resources to provide financial experience, sector knowledge, company management practice and access to 3i's network of international contacts to investee companies. 3i Nordic is part of the 3i Nordic investment team which includes investment professionals from the Helsinki and Copenhagen offices. | Investment Managers | Private Equity Investor | |
Carmel Pharma AB
![]() Carmel Pharma AB Electronic Equipment/InstrumentsElectronic Technology Carmel Pharma AB manufactures PhaSeal System, a clinically proven closed-system drug transfer device (CSTD) for the safe handling of hazardous drugs. The company expanded its safe handling initiatives to the U.S. market with the formation of Carmel Pharma, Inc., which operates a corporate office and distribution facility out of Columbus, OH. Carmel Pharma AB was founded in 1994 and is headquartered in Gothenburg, Sweden. | Electronic Equipment/Instruments | Director/Board Member | |
Global Medical Investments GMI AB
![]() Global Medical Investments GMI AB Financial ConglomeratesFinance Global Medical Investments GMI AB establishes and operates cancer centers in developing countries. It engages in the development and support of cancer management programs and cancer treatment clinics. The firm is an investment and project development company. It also secures contracts with health insurance companies and healthcare providers for private and state-run companies and government insurance agencies. The company was founded by Bror Thomas Pollare on July 24, 2009 and is headquartered in Solna, Sweden. | Financial Conglomerates | Chief Executive Officer |
Statistics
International
Sweden | 12 |
Switzerland | 10 |
United States | 9 |
Germany | 7 |
United Kingdom | 6 |
Sectoral
Health Technology | 21 |
Finance | 8 |
Consumer Services | 7 |
Miscellaneous | 4 |
Health Services | 3 |
Operational
Director/Board Member | 159 |
Chairman | 62 |
Corporate Officer/Principal | 38 |
Independent Dir/Board Member | 29 |
Private Equity Investor | 15 |
Most connected contacts
- Stock Market
- Insiders
- Tony Kennedy
- Company connections